Sinovac Biotech Ltd

Find Ratings Reports
SVA : NASDAQ : Health Care
$5.90 up 0.02 | 0.34%
Today's Range: 5.86 - 5.93
Avg. Daily Volume: 57,000
09/30/16 - 4:00 PM ET

Financial Analysis


SINOVAC BIOTECH LTD's gross profit margin for the second quarter of its fiscal year 2016 has significantly decreased when compared to the same period a year ago. Sales and net income fell significantly, underperforming compared to the average company in its industry. SINOVAC BIOTECH LTD has strong liquidity. Currently, the Quick Ratio is 1.59 which shows the ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year, indicating deteriorating cash flow.

During the same period, stockholders' equity ("net worth") has decreased by 12.28% from the same quarter last year. The key liquidity measurements indicate that the company is unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q2 FY16 Q2 FY15
Net Sales ($mil)1.3818.49
EBITDA ($mil)-12.235.56
EBIT ($mil)-13.723.81
Net Income ($mil)-9.562.27


Balance Sheet Q2 FY16 Q2 FY15
Cash & Equiv. ($mil)50.864.76
Total Assets ($mil)181.43217.71
Total Debt ($mil)29.1835.24
Equity ($mil)111.8127.46


Profitability Q2 FY16 Q2 FY15
Gross Profit Margin-62.7591.74
EBITDA Margin-887.8730.09
Operating Margin-996.5120.59
Sales Turnover0.290.3
Return on Assets-5.150.64
Return on Equity-10.181.45
Debt Q2 FY16 Q2 FY15
Current Ratio2.112.24
Debt/Capital0.210.22
Interest Expense0.40.42
Interest Coverage-34.229.05


Share Data Q2 FY16 Q2 FY15
Shares outstanding (mil)56.9156.0
Div / share0.00.0
EPS-0.170.04
Book value / share1.962.28
Institutional Own % n/a n/a
Avg Daily Volume70468.076621.0

Valuation


SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. To use another comparison, its price-to-book ratio of 2.99 indicates valuation on par with the S&P 500 average of 2.82 and a significant discount versus the industry average of 10.96. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, SINOVAC BIOTECH LTD proves to trade at a discount to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
SVA NM Peers 44.84   SVA NM Peers 22.14

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

SVA's P/E is negative making this valuation measure meaningless.

 

Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

SVA's P/CF is negative making the measure meaningless.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
SVA NA Peers 34.20   SVA NA Peers 0.50

Neutral. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth potential.

Ratio not available.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
SVA 2.99 Peers 10.96   SVA -1150.00 Peers 1.89

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

SVA is trading at a significant discount to its peers.

 

Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, SVA is expected to significantly trail its peers on the basis of its earnings growth rate.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
SVA 6.42 Peers 681.73   SVA -20.13 Peers 52.29

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

SVA is trading at a significant discount to its industry on this measurement.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

SVA significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades